ライフサイエンスコーパス: favipiravir

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 The mutant viruses remained susceptible to favipiravir.

2 reatment of monoclonal antibodies (ZMAb) and favipiravir.

3 treated with a combination of ribavirin and favipiravir.

4 in Hartley guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leadin

5 In the case of favipiravir, a polymerase inhibitor with activity agains

6 d trial, in which all patients would receive favipiravir along with standardized care.

7 Favipiravir, an antiviral developed for the treatment of

8 We found a synergistic interaction between favipiravir and ribavirin in vitro and an increased surv

9 These results suggest that favipiravir can induce norovirus mutagenesis in vivo, wh

10 All participants received oral favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d

11 roviding a proof-of-principle for the use of favipiravir derivatives or mutagenic nucleosides in the

12 upport the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.

13 One of these, T-705 (favipiravir), has a mechanism of action that is not full

14 lect data on the safety and effectiveness of favipiravir in reducing mortality and viral load in pati

15 They also suggest that favipiravir monotherapy merits further study in patients

16 ow that the broad-range antiviral nucleoside favipiravir reduces viral load in vivo by exerting antiv

17 Favipiravir remained highly effective against lethal LAS

18 In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue

19 Favipiravir suppressed Lassa virus replication in cell c

20 We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in c

21 Susceptibility to favipiravir (T-705) was assessed using plaque reduction

22 TAT2 knockout (KO) hamsters is responsive to favipiravir treatment, which protected all animals from

23 Oral favipiravir was part of the current standard of care in

24 Favipiravir was well tolerated.

25 nificantly different between adults starting favipiravir within <72 h of symptoms compared to others.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。